Transitional Liver Clinic (TLC) for Chronic Liver Disease

This study is looking at a special program called the Transitional Liver Clinic (TLC) to help patients with advanced liver disease after they leave the hospital. Many patients with serious liver problems get readmitted to the hospital soon after discharge. The TLC aims to reduce these readmissions and improve your quality of life by providing extra support from your liver doctors (Hepatology providers) and their advanced practice providers (APPs) through calls or telemedicine visits. The study will measure how many patients are readmitted to the hospital within 30 days, and also check your quality of life at 30 and 90 days after discharge using a survey. You might be able to join if you are 18 or older and have advanced liver disease, such as cirrhosis or acute alcoholic hepatitis. The current status of this study is unclear.

Study design
This study is a stepped-wedge randomized trial involving 1000 participants at four centers. Participants will be in either the usual care group or the Transitional Liver Clinic (TLC) group.
What's involved
You will be followed by telephone at 30 and 90 days after discharge from the hospital.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 90 days after discharge from their initial hospitalization.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05733832

A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease

Recruiting
NAAges 18+InterventionalTreatment
Indiana University
~1,000 participants
Updated 2025-10-24 on ClinicalTrials.gov
What's tested:Transitional Liver Clinic (TLC)

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
30-day hospital readmissions for patients hospitalized with complications of advanced liver disease
Measured over 30 days after discharge of initial hospitalization at which the participant was enrolled in the study.
+4 more outcomes measured
Liver Diseases

NCT05733832

Where you'd take part

This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Albert Einstein Healthcare Network

    Philadelphia, Pennsylvaniastudy coordinator listed

    Recruiting

  • Indiana University Division of Gastroenterolgy and Hepatology

    Indianapolis, Indianastudy coordinator listed

    Recruiting

  • University of Chicago

    Chicago, Illinoisstudy coordinator listed

    Recruiting

  • University of Michigan

    Ann Arbor, Michiganstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Eric Orman, MD · PRINCIPAL_INVESTIGATOR · Indiana University

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

biopsy
characteristic clinical, laboratory, and imaging findings 2. acute alcoholic hepatitis, defined by NIAAA Alcoholic Hepatitis Consortia, as
onset of jaundice (serum bilirubin \>3.0 mg/dL) in prior 8 weeks
consumption of \>40 (female) or 60 (male) g alcohol/day for ≥6 months, with \<60 days abstinence before jaundice onset,
AST\>50 IU/L, AST/ALT\>1.5, and both values \<400 IU/L
liver biopsy confirmation in patients with confounding factors 3. Has at least one of the following complications due to advanced liver disease occurring during hospitalization:
  • 30-day hospital readmissions for patients hospitalized with complications of advanced liver disease30 days after discharge of initial hospitalization at which the participant was enrolled in the study.

    The primary outcome, 30-day hospital readmission, is publicly reported by CMS, and is the benchmark measure in the Hospital Readmissions Reduction Program. It is therefore the most appropriate primary outcome.

  • Quality of life for patients hospitalized with complications of advanced liver disease via Promis 29+2 survey30 days after discharge of initial hospitalization at which the participant was enrolled in the study.

    This measure includes 4 items in each of 7 health domains (physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, and pain interference) as well as a single item assessing pain intensity. Each domain is scored using a T-score metric in which 50 corresponds to the average for the US population with a standard deviation of 10, and a higher T-score represents more of the concept being measured. For example, higher fatigue scores indicate more fatigue (worse quality of life), while higher physical function scores represent better physical function (better quality of life).

  • Quality of life for patients hospitalized with complications of advanced liver disease via Promis 29+2 survey90 days after discharge of initial hospitalization at which the participant was enrolled in the study

    This measure includes 4 items in each of 7 health domains (physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, and pain interference) as well as a single item assessing pain intensity. Each domain is scored using a T-score metric in which 50 corresponds to the average for the US population with a standard deviation of 10, and a higher T-score represents more of the concept being measured. For example, higher fatigue scores indicate more fatigue (worse quality of life), while higher physical function scores represent better physical function (better quality of life).

  • Patient satisfaction for patients hospitalized with complications of advanced liver disease via the PSQ 18 questionnaire30 days after discharge of initial hospitalization at which the participant was enrolled in the study

    The PSQ-18 consists of 18 items examining 7 dimensions of satisfaction with medical care: general satisfaction, technical quality, interpersonal manner, communication, financial aspects, time spent with doctor, and accessibility and convenience. Each item is scored with a 1 to 5 Likert scale and the individual item scores are averaged, with higher scores reflecting higher satisfaction.

  • Patient satisfaction for patients hospitalized with complications of advanced liver disease via the PSQ 18 questionnaire90 days after discharge of initial hospitalization at which the participant was enrolled in the study

    The PSQ-18 consists of 18 items examining 7 dimensions of satisfaction with medical care: general satisfaction, technical quality, interpersonal manner, communication, financial aspects, time spent with doctor, and accessibility and convenience. Each item is scored with a 1 to 5 Likert scale and the individual item scores are averaged, with higher scores reflecting higher satisfaction.